Holen Sie sich die Stockscreener-App
9.21
1.77%
0.18
Schlusskurs vom Vortag:
$9.03
Offen:
$9.24
24-Stunden-Volumen:
96,102
Relative Volume:
0.15
Marktkapitalisierung:
$464.23M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.751
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
-3.16%
1M Leistung:
+5.51%
6M Leistung:
+17.82%
1J Leistung:
-26.66%
1-Tages-Spanne:
$9.17
$9.4825
1-Wochen-Bereich:
$8.82
$9.6115
52-Wochen-Spanne:
$5.035
$13.15
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie RGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
9.19 | 456.14M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.27 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.25 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.10 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
725.00 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
339.67 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Q3 Earnings Forecast for REGENXBIO Issued By Leerink Partnrs - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives $28.38 Consensus Price Target from Analysts - MarketBeat
Is REGENXBIO Inc impacted by rising ratesJuly 2025 PreEarnings & Weekly High Conviction Trade Ideas - خودرو بانک
Aug Chart Watch: Is REGENXBIO Inc stock undervalued right nowRecession Risk & Technical Entry and Exit Alerts - خودرو بانک
MACD Signal: Is REGENXBIO Inc stock undervalued right nowIPO Watch & Precise Swing Trade Entry Alerts - خودرو بانک
Market Rankings: How is REGENXBIO Inc managing supply chain issuesWeekly Trend Recap & Capital Efficient Trading Techniques - خودرو بانک
US Market Wrap: Whats the beta of REGENXBIO Inc stockQuarterly Trade Review & Low Drawdown Investment Ideas - خودرو بانک
Swing Trade: Can REGENXBIO Inc. maintain sales growth2025 Key Lessons & Real-Time Chart Pattern Alerts - خودرو بانک
Profit Review: Is REGENXBIO Inc impacted by rising ratesEarnings Recap Report & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Investment Review: Is UMH Properties Inc a defensive stockExit Point & Daily Volume Surge Signals - خودرو بانک
Published on: 2025-09-16 04:03:08 - خودرو بانک
Smart Money: Is REGENXBIO Inc stock showing strong momentumJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Aug Macro: Is REGENXBIO Inc stock a good dividend stockEarnings Recap Summary & Free Verified High Yield Trade Plans - خودرو بانک
Exome Asset Management LLC Takes $2.90 Million Position in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - MarketBeat
REGENXBIO (NASDAQ:RGNX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Insider Sell: Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Ultragenyx Makes Bid for Dimension TherapeuticsBiotech Movers - TheStreet
Ieq Capital LLC Takes Position in REGENXBIO Inc. $RGNX - MarketBeat
Invesco Ltd. Purchases 27,341 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year - CGTLive®
Can REGENXBIO Inc. maintain sales growthInsider Buying & Fast Exit Strategy with Risk Control - Lancaster City Council
Is REGENXBIO Inc. in a long term uptrendTrade Volume Summary & AI Forecast Swing Trade Picks - Lancaster City Council
Regenxbio says FDA extends review date for Hunter syndrome drug - MSN
Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome - Seeking Alpha
PDT Partners LLC Buys 39,501 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Regenxbio at Morgan Stanley Conference: Gene Therapy Progress and Financial Strength - Investing.com Canada
Moving Average Crossover Confirms Uptrend in REGENXBIO Inc.July 2025 Summary & Weekly High Conviction Ideas - beatles.ru
Regenxbio stock rating reiterated at Buy by H.C. Wainwright on positive trial data - Investing.com
Pattern Scan Adds REGENXBIO Inc. to WatchlistJuly 2025 Chart Watch & Fast Gaining Stock Strategy Reports - beatles.ru
Trade Report: What is REGENXBIO Inc. s debt to equity ratio2025 Top Gainers & Weekly High Return Forecasts - 뉴스영
124,700 Shares in REGENXBIO Inc. $RGNX Bought by Nuveen LLC - MarketBeat
ADAR1 Capital Management LLC Acquires 162,423 Shares of REGENXBIO Inc. $RGNX - MarketBeat
RegenXBio (RGNX) Receives a Buy from Raymond James - The Globe and Mail
What recovery options are there for REGENXBIO Inc.2025 Risk Factors & Expert Approved Momentum Ideas - Newser
REGENXBIO Inc. recovery potential after sell offAnalyst Downgrade & Safe Entry Zone Identification - Newser
Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) - Seeking Alpha
Can REGENXBIO Inc. expand into new markets2025 Earnings Surprises & Advanced Technical Signal Analysis - خودرو بانک
Top chart patterns to watch in REGENXBIO Inc.Weekly Investment Recap & AI Optimized Trading Strategy Guides - Newser
Is REGENXBIO Inc.’s ROIC above industry averageTreasury Yields & Real-Time Stock Movement Alerts - خودرو بانک
Goldman Sachs reiterates Neutral rating on Regenxbio stock at $14 target - Investing.com Australia
REGENXBIO reports positive one-year data for MPS II gene therapy - Investing.com Nigeria
Should value investors consider REGENXBIO Inc.2025 Stock Rankings & Daily Stock Trend Reports - خودرو بانک
Goldman Sachs reiterates Neutral rating on Regenxbio stock at $14 target By Investing.com - Investing.com South Africa
Can REGENXBIO Inc. expand its profit marginsWeekly Risk Report & Free Reliable Trade Execution Plans - خودرو بانک
Regenxbio stock maintains Outperform rating at Raymond James on MPS II data - Investing.com Nigeria
Regenxbio stock maintains Outperform rating at Raymond James on MPS II data By Investing.com - Investing.com South Africa
Will REGENXBIO Inc. bounce back from current supportQuarterly Profit Summary & Safe Investment Capital Preservation Plans - Newser
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):